News

This New Pill Could Rival Ozempic and Wegovy—Will It Make Weight Loss Drugs More Accessible?
Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill from Eli Lilly could be as effective for weight loss and blood sugar control as injections like Ozempic or Wegovy,
Wegovy maker cuts weight-loss drug's price to $199, but there's a catch
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.
New obesity service to provide support and weight-loss drugs from next year
A new obesity management service allowing people to access lifestyle support as well as obesity medication if appropriate will be rolled-out next year.
Opinion
State health plan shortfall points to challenge of expensive weight loss drugs
The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she immediately signed. But the pause brought renewed attention to one of the biggest challenges in health care today, one that played a role in GIC’s woes: the high price of popular GLP-1 drugs to treat obesity.
Cigna to offer $200 Wegovy, Zepbound weight-loss benefit
Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on Wednesday.
Cigna Offers New Weight-Loss Drug Pricing Plan to Boost Use
Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will make the medicines available to more patients.
Pros and cons of popular weight loss drugs
Dr. Mike Cirigliano joins Good Day Philadelphia to discuss the latest health topics, including the pros and cons of popular weight loss drugs.
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull
Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth division announced that it would cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound.
Cigna’s Evernorth caps weight-loss drug copays at $200/month
Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo Nordisk (NVO) and Eli Lilly’s (NYSE:LLY) Zepbound.
Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests
Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...
ABC News10d
Weight-loss drugs
Novo Nordisk announced it is making the popular weight loss medication available ... with Type 2 diabetes. ABC News' Dr. Darien Sutton discusses the rise of GLP-1 weight loss drugs, when ...
Oprah Daily on MSN2d
Does Combining Hormone Therapy and a GLP-1 Boost Your Menopausal Weight Loss? Here's What the Research Says
Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...
Novo Nordisk battles Wegovy copycats through discounted prices, legal threats
Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.
Wellness companies embrace weight-loss drugs in bid to avoid fate of WeightWatchers
Health retailer The Vitamin Shoppe has seen a spike in demand for supplements that could help with loss of appetite, ...
'Golden age' of weight loss drugs coming – see which are about to get a lot cheaper
Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...
FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...